MARKET

BDSI

BDSI

BDSI
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.660
-0.020
-0.54%
After Hours: 3.660 0 0.00% 16:01 01/27 EST
OPEN
3.670
PREV CLOSE
3.680
HIGH
3.760
LOW
3.625
VOLUME
1.14M
TURNOVER
--
52 WEEK HIGH
4.675
52 WEEK LOW
2.500
MARKET CAP
361.59M
P/E (TTM)
12.22
1D
5D
1M
3M
1Y
5Y
BioDelivery Sciences Shares Soar Amid Higher-Than-Average Volumes
MT Newswires · 3d ago
53 Biggest Movers From Friday
Gainers Blue Star Foods Corp. (NASDAQ: BSFC) shares climbed 100% to close at $3.80 on Friday after gaining around 9% on Thursday.
Benzinga · 3d ago
Mid-Afternoon Market Update: Crude Oil Drops 2%; Limelight Networks Shares Spike Higher
Toward the end of trading Friday, the Dow traded down 0.59% to 34,509.34 while the NASDAQ fell 1.38% to 13,958.13. The S&P also fell, dropping, 0.99% to 4,438.28.
Benzinga · 6d ago
12 Health Care Stocks Moving In Friday's Intraday Session
 
Benzinga · 6d ago
Mid-Day Market Update: Dow Rises 100 Points; Netflix Shares Plummet
Midway through trading Friday, the Dow traded up 0.26% to 34,807.20 while the NASDAQ fell 0.24% to 14,120.10. The S&P also fell, dropping, 0.08% to 4,479.23.
Benzinga · 6d ago
34 Stocks Moving In Friday's Mid-Day Session
Gainers Blue Star Foods Corp. (NASDAQ: BSFC) shares jumped 180% to $5.32 after gaining around 9% on Thursday.
Benzinga · 6d ago
BioDelivery (BDSI) Stock Up on Raised Guidance for 2021
BioDelivery Sciences International (BDSI) raises its financial guidance for full-year 2021. BDSI expects sales at the high end of its previous guidance.
Zacks · 6d ago
HC Wainwright Adjusts BioDelivery Sciences International Price Target to $4.50 From $4, Maintains Neutral Rating
MT Newswires · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BDSI. Analyze the recent business situations of BDSI through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
85.71%Buy
14.29%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BDSI stock price target is 6.79 with a high estimate of 10.00 and a low estimate of 4.500.
High10.00
Average6.79
Low4.500
Current 3.660
EPS
Actual
Estimate
0.030.050.070.10
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 220
Institutional Holdings: 73.32M
% Owned: 74.21%
Shares Outstanding: 98.80M
TypeInstitutionsShares
Increased
53
4.24M
New
18
2.75M
Decreased
44
3.87M
Sold Out
9
1.12M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.29%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Non-Executive Chairman/Independent Director
Peter Greenleaf
President
Scott Plesha
Chief Executive Officer/Director
Jeffrey Bailey
Chief Financial Officer/Chief Accounting Officer
John Golubieski
Senior Vice President
Joseph Lockhart
Senior Vice President
Kevin Ostrander
Chief Compliance Officer/General Counsel/Secretary
James Vollins
Other
Thomas Smith
Director
Mark Sirgo
Independent Director
Todd Davis
Independent Director
Kevin Kotler
Independent Director
Vanila Singh
Independent Director
William Watson
No Data
  • All
  • Financials
  • Insiders
More
About BDSI
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company focuses on delivering therapies for individuals living with serious and debilitating chronic conditions. The Compnay builts a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA), drug-delivery technology to develop and commercialize new applications of therapies aimed at addressing important unmet medical needs. BEMA drug delivery technology consists of a small, bi-layered erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's product candidates includes BELBUCA (buprenorphine buccal film), CIII, for Chronic Pain; Symproic (naldemedine), for Opioid Induced Constipation and ONSOLIS (fentanyl buccal soluble film) for Breakthrough Cancer Pain.

Webull offers kinds of BioDelivery Sciences International, Inc. stock information, including NASDAQ:BDSI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BDSI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BDSI stock methods without spending real money on the virtual paper trading platform.